Health Care & Life Sciences » Pharmaceuticals | Marksans Pharma Ltd.

Marksans Pharma Ltd. | Income Statement

Fiscal year is April-March. All values INR Millions.
2014
2015
2016
2017
2018
Sales/Revenue
6,285
7,940
8,833
7,672
9,127
Cost of Goods Sold (COGS) incl. D&A
4,793
5,815
7,156
6,950
6,977
Gross Income
1,492
2,125
1,678
721
2,150
SG&A Expense
513
491
726
690
1,553
EBIT
967
1,627
943
24
597
Unusual Expense
-
56
-
-
-
Non Operating Income/Expense
81
100
202
186
4
Interest Expense
191
145
102
57
102
Pretax Income
864
1,559
1,069
155
498
Income Tax
128
439
241
35
140
Consolidated Net Income
736
1,120
827
120
358
Net Income
719
1,094
785
95
358
Net Income After Extraordinaries
719
1,094
785
95
358
Net Income Available to Common
719
1,085
785
95
358
EPS (Basic)
1.87
2.65
1.92
0.23
0.80
Basic Shares Outstanding
385
409
409
409
-
EPS (Diluted)
1.87
2.65
1.92
0.23
-
Diluted Shares Outstanding
385
409
409
409
-
EBITDA
1,124
1,788
1,224
325
865
Other Operating Expense
11
8
8
8
-
Non-Operating Interest Income
7
33
25
2
-
Minority Interest Expense
17
26
42
25
-
Preferred Dividends
-
9
-
-
-

About Marksans Pharma

View Profile
Address
11th Floor Grandeur
Mumbai Maharashtra 400053
India
Employees -
Website http://www.marksanspharma.com
Updated 09/14/2018
Marksans Pharma Ltd. engages in the research, manufacture, marketing, and sale of pharmaceutical formulations. Its product portfolio spreads over major therapeutic areas such as oncology, gastroenterology, anti-diabetic, cardiovascular, pain management, and gynecology. The company was founded by Mark Saldanha on April 16, 1992 and is headquartered in Mumbai, India.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.